SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:oru-85159"
 

Sökning: onr:"swepub:oai:DiVA.org:oru-85159" > Molecular Epidemiol...

Molecular Epidemiology and Mechanisms of Antibiotic Resistance in Clinical Isolates of Pseudomonas aeruginosa from Qatar

Sid Ahmed, Mazen, 1970- (författare)
Örebro universitet,Institutionen för naturvetenskap och teknik
Jass, Jana, professor, 1963- (preses)
Örebro universitet,Institutionen för naturvetenskap och teknik
Ibrahim, Emad, dr (preses)
Division of Microbiology, Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar; Department of Microbiology and Immunology, Weill Cornell Medicine-Qatar, Doha, Qatar
visa fler...
Sultan, Ali, dr (preses)
Department of Microbiology and Immunology, Weill Cornell Medicine-Qatar, Doha, Qatar
Söderquist, Bo, professor, 1955- (preses)
Örebro universitet,Institutionen för medicinska vetenskaper
Giske, Christian, professor (opponent)
Klin. Mikrobiologi, Karolinska Institutet, Stockholm, Sweden
visa färre...
 (creator_code:org_t)
ISBN 9789175293530
Örebro : Örebro University, 2020
Engelska 92 s.
Serie: Örebro Studies in Life Science, 1653-3100 ; 17
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)
Abstract Ämnesord
Stäng  
  • Inappropriate and excessive use of antibiotics promotes antimicrobial resistance (AMR), particularly in Gram-negative bacteria (GNB). There is a noticeable increase in nosocomial infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa, which is associated with significant morbidity, mortality, and an increase in cost management. Although this is a global problem, there is a lack of sufficient data on regional differences that can contribute towards effective AMR management. This thesis presents a study of MDR-P. aeruginosa at five different hospitals in Qatar conducted prospectively between October 2014 - September 2017. The aim was to study the epidemiology, microbiological and clinical characteristics of MDR-P. aeruginosa infections as well as investigate the activity of new antibiotic combinations against these bacteria. The prevalence of MDR-P. aeruginosa isolates in the first year was 8.1% (205/2533), isolated from different clinical specimens, but the majority were from respiratory infections (44.9%, n=92). Most cases were exposed to antibiotics during the 90 days prior to isolation (85.4%, n=177), and the resistance to cefepime, ciprofloxacin, piperacillin/tazobactam, meropenem was >90%. To compare pre- and post-Antimicrobial Stewardship Program, there was a significant reduction in antibiotic consumption by 30.4% of total inpatient antibiotic prescriptions (p=0.008) and the prevalence of MDR-P. aeruginosa significantly declined from 9% to 5.4% (p=0.019). The in vitro investigation of ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) against MDR-P. aeruginosa isolates, showed promising results with susceptibility of 68.8% (n=141/205) and 62.9% (n=129/205), respectively, which was higher than other antipseudomonal agents except colistin. Seventy-five isolates that were sequenced belonged to 29 different sequence types, with ST235 being predominant at 21.3% (16/75). Among the 42 isolates that were resistant to CZA and/or C/T, the most prevalent genes were blaOXA-488 and blaVEB-9 detected in 45.2% (19/42) of isolates. Spearman’s analysis showed that resistance to CZA and C/T were positively correlated with the presence of blaOXA-10, blaPDC-2a, blaVIM-2, and blaVEB-9 , respectively. The study highlights potential key mechanisms that could explain the resistance of MDR-P. aeruginosa to the new antibiotic combinations.

Ämnesord

NATURVETENSKAP  -- Biologi -- Annan biologi (hsv//swe)
NATURAL SCIENCES  -- Biological Sciences -- Other Biological Topics (hsv//eng)

Nyckelord

Antibiotics
C/T
CZA
MDR
Pseudomonas aeruginosa
ST235
VEB
VIM

Publikations- och innehållstyp

vet (ämneskategori)
dok (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy